Evidence that the p53 negative / Bcl-2 positive phenotype is an independent indicator of good prognosis in colorectal ca
- PDF / 1,498,110 Bytes
- 10 Pages / 610 x 792 pts Page_size
- 20 Downloads / 169 Views
Open Access
Research
Evidence that the p53 negative / Bcl-2 positive phenotype is an independent indicator of good prognosis in colorectal cancer: A tissue microarray study of 460 patients Nicholas FS Watson*1,2, Zahra Madjd1, Duncan Scrimegour1, Ian Spendlove1, Ian O Ellis3, John H Scholefield2 and Lindy G Durrant1 Address: 1Academic Department of Clinical Oncology, University of Nottingham, City Hospital, Nottingham, NG5 1PB, UK, 2Section of Gastrointestinal Surgery, University of Nottingham, Queens' Medical Centre, Nottingham, NG7 2UH, UK and 3Department of Pathology, City Hospital, Nottingham, NG5 1PB, UK Email: Nicholas FS Watson* - [email protected]; Zahra Madjd - [email protected]; Duncan Scrimegour - [email protected]; Ian Spendlove - [email protected]; Ian O Ellis - [email protected]; John H Scholefield - [email protected]; Lindy G Durrant - [email protected] * Corresponding author
Published: 19 July 2005 World Journal of Surgical Oncology 2005, 3:47 47
doi:10.1186/1477-7819-3-
Received: 01 April 2005 Accepted: 19 July 2005
This article is available from: http://www.wjso.com/content/3/1/47 © 2005 Watson et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract Background: Advances in our understanding of the molecular biology of colorectal cancer have fuelled the search for novel molecular prognostic markers to complement existing staging systems. Markers assessed in combination may perform better than those considered individually. Using high-throughput tissue microarray technology, we describe the prognostic value of combined p53 / Bcl-2 status in colorectal cancer. Patients and methods: Tumour samples from 462 patients who underwent elective surgery to resect a primary colorectal cancer between 1994 and 2000 (mean follow-up of 75 months) were assembled in tissue microarray format. Clinico-pathological data including tumour grade, stage, vascular invasion status along with disease specific survival data has been collected prospectively. Immunohistochemical analysis of p53 and Bcl-2 expression was performed using antibodies DO-7 (p53) and 124 (Bcl-2), and results correlated with known clinico-pathological variables and outcomes. Results: Abnormal nuclear p53 accumulation and Bcl-2 overexpression were detected in 221/445 (49.6%) and199/437 (45.5%) tumours respectively, with a significant inverse correlation between the two markers (p = 0.023). On univariate analysis no correlations were found between either marker and standard clinico-pathological variables, however nuclear p53 expression was associated with a significantly reduced survival (p = 0.024). Combined analysis of the two markers indicated that 112/432 (24.2%) cases displayed a p53(-)/Bcl-2(+) pheno
Data Loading...
